科研之友
微信
新浪微博
Facebook
分享链接
摘要
IMPORTANCE There are no medications approved for treating cannabis dependence or withdrawal. The cannabis extract nabiximols (Sativex), developed as a multiple sclerosis treatment, offers a potential agonist medication for cannabis withdrawal. %26lt;br%26gt;OBJECTIVE To evaluate the safety and efficacy of nabiximols in treating cannabis withdrawal. %26lt;br%26gt;DESIGN, SETTING, AND PARTICIPANTS A 2-site, double-blind randomized clinical inpatient trial with a 28-day follow-up was conducted in New South Wales, Australia. Participants included 51 DSM-IV-TR cannabis-dependent treatment seekers. %26lt;br%26gt;INTERVENTIONS A 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Delta 9-tetrahydrocannabinol and 80 mg of cannabidiol) or placebo with standardized psychosocial interventions during a 9-day admission. %26lt;br%26gt;MAIN OUTCOMES AND MEASURES Severity of cannabis withdrawal and cravings (Cannabis Withdrawal Scale), retention in withdrawal treatment, and adverse events. Secondary outcomes include postwithdrawal cannabis use, health outcomes, and psychosocial outcomes. %26lt;br%26gt;RESULTS Nabiximols treatment significantly reduced the overall severity of cannabis withdrawal relative to placebo (F-8,F-377.97 = 2.39; P = .01), including effects on withdrawal-related irritability, depression, and cannabis cravings. Nabiximols had a more limited, but still positive, therapeutic benefit on sleep disturbance, anxiety, appetite loss, physical symptoms, and restlessness. Nabiximols patients remained in treatment longer during medication use (unadjusted hazard ratio, 3.66 [95% CI, 1.18-11.37]; P = .02), with 2.84 the number needed to treat to achieve successful retention in treatment. Participants could not reliably differentiate between nabiximols and placebo treatment (chi(2)(1) = 0.79; P = .67), and those receiving nabiximols did not report greater intoxication (F-1,F-6 = 0.22; P = .97). The number (F-1,F-50 = 0.3; P = .59) and severity (F-1,F-50 = 2.69; P = .10) of adverse events did not differ significantly between groups. Both groups showed reduced cannabis use at follow-up, with no advantage of nabiximols over placebo for self-reported cannabis use (F-1,F-48 = 0.29; P = .75), cannabis-related problems (F-1,F-49 = 2.33; P = .14), or cannabis dependence (F-1,F-50 %26lt; 0.01; P = .89). %26lt;br%26gt;CONCLUSIONS AND RELEVANCE In a treatment-seeking cohort, nabiximols attenuated cannabis withdrawal symptoms and improved patient retention in treatment. However, placebo was as effective as nabiximols in promoting long-term reductions in cannabis use following medication cessation. The data support further evaluation of nabiximols for management of cannabis dependence and withdrawal in treatment-seeking populations.
- 出版日期2014-3
